|
01-2025
|
Kamada 008 Study Task Order #1
Kamada 008 Study Task Order #1
|
|
01-2024
|
INHIBRX Advisory Meeting
INHIBRX Advisory Meeting
|
|
01-2024
|
Intellia Consulting Agreement
Intellia Consulting Agreement
|
|
12-2023
|
Novel biomarkers for alpha 1-antitrypsin mediated liver disease in circulating exosomes
Novel biomarkers for alpha 1-antitrypsin mediated liver disease in circulating exosomes
|
|
08-2023
|
Takeda Consulting Agreement
Takeda Consulting Agreement
|
|
03-2023
|
Liver and AAT Deficiency
Liver and AAT Deficiency
|
|
02-2023
|
BAL Testing for Inhibrx rhAAT-Fc (INBRX-101)
BAL Testing for Inhibrx rhAAT-Fc (INBRX-101)
|
|
12-2022
|
A high concentration of a-defensins impairs macrophage differentiation and function in AATD individuals
A high concentration of a-defensins impairs macrophage differentiation and function in AATD individuals
|
|
12-2022
|
01040902
01040902
|
|
10-2022
|
Dicerna Pharmaceuticals Consulting Agreement
Dicerna Pharmaceuticals Consulting Agreement
|
|
10-2022
|
Vertex AAT Steering Committee Agreement
Vertex AAT Steering Committee Agreement
|
|
09-2022
|
Adverum AAT Testing (ADVM-043-01)
Adverum AAT Testing (ADVM-043-01)
|
|
06-2022
|
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease Subcontract
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease Subcontract
|
|
12-2021
|
Apic Bio Research Agreement
Apic Bio Research Agreement
|
|
10-2021
|
A Master Protocol Assessing The Safety, Tolerability, And Efficacy of Anti-Spike (S) SARS-COV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19
A Master Protocol Assessing The Safety, Tolerability, And Efficacy of Anti-Spike (S) SARS-COV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19
|
|
09-2021
|
Dicerna A1AT-101 Study
Dicerna A1AT-101 Study
|
|
06-2021
|
Alpha-1 Coded Testing (ACT) Study
Alpha-1 Coded Testing (ACT) Study
|
|
06-2021
|
Alpha-1 Foundation DNATB 19-20
Alpha-1 Foundation DNATB 19-20
|
|
06-2021
|
CTSI Institutional Support
CTSI Institutional Support
|
|
06-2021
|
Pulmonary Med Cystic Fibrosis
Pulmonary Med Cystic Fibrosis
|
|
03-2021
|
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19
|
|
12-2020
|
CTSI
CTSI
|
|
11-2020
|
Brantly MD, Mark CAG (AAT Steering Committee)
Brantly MD, Mark CAG (AAT Steering Committee)
|
|
10-2020
|
Quintiles Independent Contractor Agreement - Protocol 471101 (Quintiles Project Code: JXA36454)
Quintiles Independent Contractor Agreement - Protocol 471101 (Quintiles Project Code: JXA36454)
|
|
08-2020
|
Takeda Consultant Project Services Agreement (PSA) | US Alpha-1 #Medical Advisory Board | Mark Brantly
Takeda Consultant Project Services Agreement (PSA) | US Alpha-1 #Medical Advisory Board | Mark Brantly
|
|
06-2020
|
Alpha One Professorship UFF Fund 7320
Alpha One Professorship UFF Fund 7320
|
|
05-2020
|
Alpha 1 Liver Biopsy Slides
Alpha 1 Liver Biopsy Slides
|
|
03-2020
|
The Role of Conformational Diseases on Macrophage Function
The Role of Conformational Diseases on Macrophage Function
|
|
03-2020
|
Lung Transplant Research Fund UFF 8263
Lung Transplant Research Fund UFF 8263
|
|
01-2020
|
Alpha-1 Research Program Multiple Sponsors Project
Alpha-1 Research Program Multiple Sponsors Project
|
|
12-2019
|
Kamada Consulting Master Agreement
Kamada Consulting Master Agreement
|
|
10-2019
|
Vertex Advisory Board Agreement for AATD Liver Disease Advisory Board July 18, 2019
Vertex Advisory Board Agreement for AATD Liver Disease Advisory Board July 18, 2019
|
|
06-2019
|
Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage
Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage
|
|
06-2019
|
Alpha-1 Foundation DNA and Tissue Bank Agreement 2016-2019
Alpha-1 Foundation DNA and Tissue Bank Agreement 2016-2019
|
|
06-2019
|
THE EFFECT OF OBESITY ON IMMUNE RESPONSES IN PNEUMOCOCCALPOLYSACCHARIDE VACCINE
THE EFFECT OF OBESITY ON IMMUNE RESPONSES IN PNEUMOCOCCALPOLYSACCHARIDE VACCINE
|
|
02-2019
|
Vertex Consulting Agreement
Vertex Consulting Agreement
|
|
09-2018
|
Assay Validation Service for Inhibrx Phase 1 Clinical Study of rhAAT-FC (INBRX-101)
Assay Validation Service for Inhibrx Phase 1 Clinical Study of rhAAT-FC (INBRX-101)
|
|
10-2017
|
A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha1-Proteinase Inhibitor (Human) Compared to Prolastin-? C in Subjects with Alpha1-Antitrypsin Deficiency
A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha1-Proteinase Inhibitor (Human) Compared to Prolastin-? C in Subjects with Alpha1-Antitrypsin Deficiency
|
|
04-2017
|
Phase II, double-blind, placebo-controlled study to explore the ELF and plasma concentration as well as safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency subjects
Phase II, double-blind, placebo-controlled study to explore the ELF and plasma concentration as well as safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency subjects
|
|
01-2017
|
Alpha-1 Antitrypsin in African Americans and Hispanics
Alpha-1 Antitrypsin in African Americans and Hispanics
|
|
12-2016
|
Kamada-inhaled 006 Laboratory Testing Service Agreement
Kamada-inhaled 006 Laboratory Testing Service Agreement
|
|
12-2016
|
Kamada 007-EU Laboratory Testing Service Agreement for A1RP-INST-AAT-007
Kamada 007-EU Laboratory Testing Service Agreement for A1RP-INST-AAT-007
|
|
12-2016
|
Reference Laboratory for "A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha-1 Antitrypsin Deficiency
Reference Laboratory for "A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha-1 Antitrypsin Deficiency
|
|
07-2016
|
Alpha-1 Antirypsin Deficiency: Understanding and
Alpha-1 Antirypsin Deficiency: Understanding and
|
|
07-2016
|
A Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin
A Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin
|
|
06-2016
|
Alpha-1 Foundation DNA and Tissue Bank 13-16
Alpha-1 Foundation DNA and Tissue Bank 13-16
|
|
06-2016
|
ACT Program Testing Service Grant Agreement
ACT Program Testing Service Grant Agreement
|
|
06-2016
|
State of Florida Testing Service Grant Agreement
State of Florida Testing Service Grant Agreement
|
|
01-2016
|
An Open-Label Extension Study of the Long Term Safety of
An Open-Label Extension Study of the Long Term Safety of
|
|
10-2015
|
Intermune PIPF-031
Intermune PIPF-031
|
|
08-2015
|
The Effect of Short-Term Atorvastatin Treatment on Immun
The Effect of Short-Term Atorvastatin Treatment on Immun
|
|
07-2015
|
LRRI Testing
LRRI Testing
|
|
06-2015
|
Stromedix-003_Brantly_Randomized, Double-Blind, Placebo
Stromedix-003_Brantly_Randomized, Double-Blind, Placebo
|
|
03-2015
|
BMS-986020-Brantly
BMS-986020-Brantly
|
|
01-2015
|
AAT Lab Services Agreement - HICL
AAT Lab Services Agreement - HICL
|
|
09-2014
|
PIPF-016: A Randomized, Double Blind, Placebo-Controlled
PIPF-016: A Randomized, Double Blind, Placebo-Controlled
|
|
06-2014
|
UF Adult Cystic Fibrosis Center-Acct CC109-13AD
UF Adult Cystic Fibrosis Center-Acct CC109-13AD
|
|
06-2014
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
10-2013
|
Talecris SPARK STUDY:A Multi-center, Randomized, Double-
Talecris SPARK STUDY:A Multi-center, Randomized, Double-
|
|
06-2013
|
UF Adult Cystic Fibrosis Center-Acct C023-12AD
UF Adult Cystic Fibrosis Center-Acct C023-12AD
|
|
06-2013
|
ACT Program Testing Service Grant Agreement
ACT Program Testing Service Grant Agreement
|
|
06-2013
|
State of Florida Testing Service Grant Agreement
State of Florida Testing Service Grant Agreement
|
|
12-2012
|
A 52-Week, Double-Blind, Randomized, Placebo-Controlled,
A 52-Week, Double-Blind, Randomized, Placebo-Controlled,
|
|
08-2012
|
THE ALPHA-1 FOUNDATION QUANTUM-1 STUDY
THE ALPHA-1 FOUNDATION QUANTUM-1 STUDY
|
|
06-2012
|
UF Adult Cystic Fibrosis Center
UF Adult Cystic Fibrosis Center
|
|
06-2012
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
06-2011
|
Center of Excellence in Lung Transplantation
Center of Excellence in Lung Transplantation
|
|
06-2011
|
UF Adult Cystic Fibrosis Center
UF Adult Cystic Fibrosis Center
|
|
06-2011
|
MILES Trial
MILES Trial
|
|
05-2011
|
NAC40630
NAC40630
|
|
05-2011
|
Talecris Reconciliation Letter for BREATH Study
Talecris Reconciliation Letter for BREATH Study
|
|
02-2011
|
Aztreonam
Aztreonam
|
|
12-2010
|
Targeted Detection of Alpha-1 Antitrypsin Deficiency in
Targeted Detection of Alpha-1 Antitrypsin Deficiency in
|
|
12-2010
|
Targeted Detection of Alpha-1 Antitrypsin Deficiency in
Targeted Detection of Alpha-1 Antitrypsin Deficiency in
|
|
12-2010
|
Preclinical and Phase I/II Trials of AAV1-AAT Vectors
Preclinical and Phase I/II Trials of AAV1-AAT Vectors
|
|
10-2010
|
Phase II/III Randomized Double-Blind Comparison of Alpha
Phase II/III Randomized Double-Blind Comparison of Alpha
|
|
07-2010
|
Quantitative chest computed tomography Unmasking Emphyse
Quantitative chest computed tomography Unmasking Emphyse
|
|
06-2010
|
Washington University- Senior AAT Lab Services Agreement
Washington University- Senior AAT Lab Services Agreement
|
|
06-2010
|
ACT Program Testing Service Grant Agreement
ACT Program Testing Service Grant Agreement
|
|
06-2010
|
Alpha-1 Florida Detection Program
Alpha-1 Florida Detection Program
|
|
06-2010
|
The Multicenter International Lymphangioleiomyomatosis
The Multicenter International Lymphangioleiomyomatosis
|
|
03-2010
|
PIPF-006, A Randomized, Double-Blind, Placebo-Controlled
PIPF-006, A Randomized, Double-Blind, Placebo-Controlled
|
|
01-2010
|
Laboratory Services Agreement for Kamada s Phase II/III
Laboratory Services Agreement for Kamada s Phase II/III
|
|
01-2010
|
GENETIC MODIFIERS OF THE ALPHA 1-ANTITRYPSIN DEFICIENCY
GENETIC MODIFIERS OF THE ALPHA 1-ANTITRYPSIN DEFICIENCY
|
|
12-2009
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
09-2009
|
Therapeutic small molecules for alpha-1antitrypsin defic
Therapeutic small molecules for alpha-1antitrypsin defic
|
|
05-2009
|
A Phase 4 Study to evaluate the effect of weekly augment
A Phase 4 Study to evaluate the effect of weekly augment
|
|
01-2009
|
HIV/AAT Laboratory Service Agreement
HIV/AAT Laboratory Service Agreement
|
|
12-2008
|
Alpha-1 State of Florida Detection Program
Alpha-1 State of Florida Detection Program
|
|
12-2008
|
Reference Laboratory for the Alpha-1 Coded Tested Trial
Reference Laboratory for the Alpha-1 Coded Tested Trial
|
|
06-2008
|
Alpha-1 Antitrypsin Genetics Laboratory Service Agreemen
Alpha-1 Antitrypsin Genetics Laboratory Service Agreemen
|
|
06-2008
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
05-2008
|
Multi-center, randomized, double blind crossover trial
Multi-center, randomized, double blind crossover trial
|
|
05-2008
|
Multi-center, open-label trial to evaluate the safety
Multi-center, open-label trial to evaluate the safety
|
|
03-2008
|
Preclinical and Phase I/II Trials of AAV-AAT Vectors
Preclinical and Phase I/II Trials of AAV-AAT Vectors
|
|
03-2008
|
PRECLINICAL and PHASE I/II TRIALS OF AAV-AAT VECTORS
PRECLINICAL and PHASE I/II TRIALS OF AAV-AAT VECTORS
|
|
12-2007
|
Alpha-1 State of Florida Detection Program
Alpha-1 State of Florida Detection Program
|
|
12-2007
|
Reference Laboratory for the Alpha-1 Coded Tested Trial
Reference Laboratory for the Alpha-1 Coded Tested Trial
|
|
07-2007
|
THE ANTI-INFLAMMATORY ROLE OF ALPHA-1 ANTITRYPSIN IN THE
THE ANTI-INFLAMMATORY ROLE OF ALPHA-1 ANTITRYPSIN IN THE
|
|
06-2007
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
03-2007
|
TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENT
TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENT
|
|
12-2006
|
Alpha-1 State of Florida Detection Program
Alpha-1 State of Florida Detection Program
|
|
09-2006
|
Alpha-1 State of Florida Detection Program
Alpha-1 State of Florida Detection Program
|
|
09-2006
|
Reference Laboratory for the Alpha-1 Coded Tested Trial
Reference Laboratory for the Alpha-1 Coded Tested Trial
|
|
06-2006
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
06-2006
|
NEUTROPHIL APOPTOSIS AND NEONATAL INFLAMMATION
NEUTROPHIL APOPTOSIS AND NEONATAL INFLAMMATION
|
|
06-2006
|
MAPPING THE ROLE OF UNFOLDED PROTEIN RESPONSE GENES IN
MAPPING THE ROLE OF UNFOLDED PROTEIN RESPONSE GENES IN
|
|
03-2006
|
A PHASE 1B/2A STUDY TO EVALUATE THE EFFECT OF
A PHASE 1B/2A STUDY TO EVALUATE THE EFFECT OF
|
|
03-2006
|
4-PHENYL BUTYRATE MEDIATED SECRETION RESCUE IN ALPHA 1-A
4-PHENYL BUTYRATE MEDIATED SECRETION RESCUE IN ALPHA 1-A
|
|
02-2006
|
PHASE 1B/2A..AEROSOLIZED, RECOMBINANT ALPHA-1ANTITRYPSIN
PHASE 1B/2A..AEROSOLIZED, RECOMBINANT ALPHA-1ANTITRYPSIN
|
|
12-2005
|
Alpha-1 State of Florida Detection Program
Alpha-1 State of Florida Detection Program
|
|
12-2005
|
Reference Laboratory for the Alpha-1 Coded Tested Trial
Reference Laboratory for the Alpha-1 Coded Tested Trial
|
|
10-2005
|
PHASE I SAFETY INVESTIGATION OF AN AEROLIZED, RECOMBINAN
PHASE I SAFETY INVESTIGATION OF AN AEROLIZED, RECOMBINAN
|
|
09-2005
|
FINE MAPPING OF COPD SUSCEPTIBILITY GENES
FINE MAPPING OF COPD SUSCEPTIBILITY GENES
|
|
09-2005
|
ALPHA-1 FOUNDAITON DNA AND TISSUE BANK
ALPHA-1 FOUNDAITON DNA AND TISSUE BANK
|
|
07-2005
|
ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY
ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY
|
|
07-2005
|
RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES
RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES
|
|
06-2005
|
Alpha-1 Foundation DNA and Tissue Bank
Alpha-1 Foundation DNA and Tissue Bank
|
|
09-2004
|
LABORATORY SERVICES AGREEMENT
LABORATORY SERVICES AGREEMENT
|
|
07-2004
|
THE ROLE OF APOPTOSIS IN LUNG INFLAMMATION AND INJURY IN
THE ROLE OF APOPTOSIS IN LUNG INFLAMMATION AND INJURY IN
|
|
06-2004
|
ALPHA-1 FOUNDATION DNA and TISSUE BANK
ALPHA-1 FOUNDATION DNA and TISSUE BANK
|
|
06-2004
|
STATE OF FLORIDA ALPHA 1 DETECTION PROGRAM UNDER STATE O
STATE OF FLORIDA ALPHA 1 DETECTION PROGRAM UNDER STATE O
|
|
06-2004
|
THE PHARMACOKINETICS AND SAFETY OF AN ALPH-1 PROTEINASE
THE PHARMACOKINETICS AND SAFETY OF AN ALPH-1 PROTEINASE
|
|
05-2004
|
UNIVERSITY OF FLORIDA ALPHAL- ANTITRYPSIN DEFICIENCY LAB
UNIVERSITY OF FLORIDA ALPHAL- ANTITRYPSIN DEFICIENCY LAB
|
|
05-2004
|
ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY
ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY
|
|
04-2004
|
COMPARATIVE MICROARRAY ANALYSIS OF GLOBAL LIVER GENE EXP
COMPARATIVE MICROARRAY ANALYSIS OF GLOBAL LIVER GENE EXP
|
|
08-2003
|
COPD AND AN INVESTIGATIONAL DRUG BY AMGEN
COPD AND AN INVESTIGATIONAL DRUG BY AMGEN
|
|
06-2003
|
MOLECULAR THERAPIES FOR ALPHA 1-ANTITRYPSIN LIVER DISEAS
MOLECULAR THERAPIES FOR ALPHA 1-ANTITRYPSIN LIVER DISEAS
|
|
06-2003
|
CHARACTERIZATION OF LOWER RESPIRATORY TRACT INHIBITION
CHARACTERIZATION OF LOWER RESPIRATORY TRACT INHIBITION
|
|
05-2003
|
ALPHA ONE FOUNDATION SUBCONTRACT FOR STATE OF FLORIDA
ALPHA ONE FOUNDATION SUBCONTRACT FOR STATE OF FLORIDA
|
|
02-2003
|
ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY
ALPHA-1 ANTITRYPSIN DEFICIENCY LABORATORY
|
|
07-2002
|
RESEARCH NURSE SALARY
RESEARCH NURSE SALARY
|
|
05-2002
|
AAT MATCHING FUNDS
AAT MATCHING FUNDS
|
|
03-2002
|
RNDMZD CNTRL MULTI-CTR STDY TO COMPARE THE BIOCHEMICAL E
RNDMZD CNTRL MULTI-CTR STDY TO COMPARE THE BIOCHEMICAL E
|
|
03-2002
|
SUPPLEMENTAL FUNDS (IV STUDY) FOR LAB SERV AGREE TO PERF
SUPPLEMENTAL FUNDS (IV STUDY) FOR LAB SERV AGREE TO PERF
|
|
01-2002
|
DBL-BL RNDMZD PLCB-CNTRL DOSE ESCALATION STDY TO ASSES T
DBL-BL RNDMZD PLCB-CNTRL DOSE ESCALATION STDY TO ASSES T
|
|
10-2001
|
STUDY TO ASSESS BIOCHEMICAL MARKERS IN EPITHELIAL LINING
STUDY TO ASSESS BIOCHEMICAL MARKERS IN EPITHELIAL LINING
|
|
12-2000
|
VENTIS BEHRING (CENTEON) LABORATORY TESTING AGREEMENT
VENTIS BEHRING (CENTEON) LABORATORY TESTING AGREEMENT
|
|
05-2000
|
AUGMENTATION THERPY FOR CONGENITAL ALPHA1-PROTEINASE
AUGMENTATION THERPY FOR CONGENITAL ALPHA1-PROTEINASE
|
|
08-1999
|
RNDMZD CONTRLD MULTI-CTR STDY TO COMPAR THE BIOCHEMICAL
RNDMZD CONTRLD MULTI-CTR STDY TO COMPAR THE BIOCHEMICAL
|
